Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2013

View Archived Issues

Mirabegron/solifenacin as an effective therapeutic option for overactive bladder

Imanova presents novel imaging tracer candidates

NIHR collaborates with companies on Alzheimer disease biomarker discovery

One-step generation of transgenic mice with multiple mutations

Vectura establishes strategic partnership in China for new respiratory business

The discovery of an antimicrobial adjuvant for sensitizing multidrug-resistant bacteria

Takeda Pharmaceutical presents highlights of fiscal 2012

New phase III study evaluates Stivarga in advanced hepatocellular carcinoma

Two new trials under way in sarilumab phase III program

OncoMed's anti-Notch 2/3 antibody OMP-59R5 begins study in SCLC

Herbal cream safely and effectively relieves symptoms of psoriasis

NP-260 shows efficacy in animal models of neuropathic pain

Soligenix begins phase I study of SGX-203 in pediatric Crohn's disease

Ultragenyx to conduct phase I/II trial of UX-003 for MPS VII

Elixir Medical receives CE mark approval for the DESolve Scaffold System

Ono Pharmaceutical updates developments of fourth quarter 2012

TaiGen seeks approval for oral formulation of nemonoxacin in Taiwan and China

Sanofi discloses novel PKC-beta inhibitors

Merck & Co. patents novel OX2 receptor antagonists

Chinese group presents new DGAT1 inhibitors

Researchers at Torrent Pharmaceuticals synthesize new TGR5 agonists

NewVac patents novel A2A receptor antagonists

Janssen obtains FDA approval for use of Simponi in new indication

FDA approves Xofigo in treatment of CRPC with bone metastases

XBiotech reports results on use of Xilonix in treatment-refractory NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...